Buradasınız

Anasayfa » Content

Meme kanserinin tespitinde Tc-99m MIBI meme sintigrafisi, mamografi ve ultrasonografi yöntemlerinin etkinliklerinin karşılaştırılması

Comparison of Tc 99m MIBI scintomammography, mammography and ultrasonography in detection of breast carcinoma

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
However breast carcinoma is the most common neoplasm found among women, improvements in diagnostic and therapeutic methods decreased the mortality rates. Although, mammography and ultrasonography are the most widely used methods for screening and diagnosing breast cancer; images of benign and malignant lesions can be similar in both methods and frequently result in negative biopsies. It is important to reduce the negative result ratios by using non-invasive diagnostic methods. por this purpose scintomammography and PET scanning methods by using different radionuclides can be perform. The aim of this study was to compare the specificity and sensitivity of mammography, ultrasonography and Technetium-99m- hexakis-2-methoxy-isobutyl-isonitrile (Tc-99m MIBI) scintomammography methods in patients with palpable breast mass in detection of benign and malignant lesions retrospectively. A total 84 patients (mean age of 49.63+11.33 years) with palpable breast masses were studied. Mammography, ultrasonography and Tc-99m MIBI scintomammography were performed to all patients. Histopathological examination revealed malignancy in 30 patients and benign disease in 54 patients. In the detection of malignancy; sensitivity and specificity of scintomammography, mammography and ultrasonography were 93% and 91%, 83% and 85%, 87% and 89% respectively. Using a combination of three tests, the combined sensitivity and specificity was increased to 97% and 96%. In conclusion scintomammography might be a complementary method for suspicious lesions in mammography and ultrasonography in deciding which lesions require a biopsy.
Bookmark/Search this post with
Abstract (Original Language): 
Meme kanseri tüm dünya kadınları arasında en sık görülen kanser türü olmakla birlikte bu hastalığa bağlı mortalite oranı, erken tanı ve tedavideki gelişmeler sayesinde azalmıştır. Mamografi ve ultrasonografi meme kanseri taraması ve tanısında en sık kullanılan görüntüleme yöntemleri olmasına karşın her iki yöntemde de benign ve malign lezyonlar benzer görünümde olabilmekte ve bu da gereksiz fazla sayıda negatif biyopsi alınmasına sebep olmaktadır. Non-invaziv yöntemler kullanılarak, biyopsiden yararlanabilecek hastaların seçimi ve negatif sonuçlu biyopsi sayısının azaltılması önemlidir. Bu amaçla çeşitli radyonüklidler kullanılarak meme sintigrafisi ve pozitron emisyon tomografi yöntemleri uygulanmaktadır. Bu çalışmada memede ele gelen kitle nedeniyle kliniklere başvuran hastaların lezyonlarının benign, malign ayrımında mamografi, ultrasonografi ve Technetium-99m- hexakis-2-methoxy-isobutyl-isonitrile (Tc-99m MIBI) ile yapılan meme sintigrafisi bulguları retrospektif olarak değerlendirilmiş ve etkinliklerinin karşılaştırılması amaçlanmıştır. Bu amaçla biyopsi sonuçları mevcut olan 84 olgunun (yaş ortalaması 49.63+11.33 yıl) mamografi, ultrasonografi ve Tc-99m MIBI meme sintigrafisi sonuçları değerlendirildi. Elli dört hastanın histopatolojik incelemesi benign, 30 hastanın malign olarak tespit edildi. Meme sintigrafisinde malignite için sensitivite %93, spesifite %91, mamografide sensitivite %83, spesifite %85 ve ultrasonografide sensitivite %87, spesifite %89 olarak bulundu. Her üç yöntem kombine edildiğinde ise sensitivite ve spesifite değerlerinin, %97 ve %96' ya yükseldiği tespit edildi. Sonuç olarak meme sintigrafisinin palpabl meme kitlelerinin tespitinde şüpheli mamogram ve ultrasonografiye sahip, meme kanseri açısından yüksek risk taşıyan kadınlarda, lezyonun biyopsi öncesi malignite açısından natürünü ortaya koymak amacıyla kullanımı önerilebilir.
FULL TEXT (PDF): 
PDF icon arastirmax-meme-kanserinin-tespitinde-tc-99m-mibi-meme-sintigrafisi-mamografi-ultrasonografi-yontemlerinin-etkinliklerinin-karsilastirilmasi.pdf
  • 3
1-6
  • Turkish

REFERENCES

References: 

1.
JemalA
, MurrayT, WardE,SamuelsA,Tiwari RC, Ghafoor A al. Cancer statistics. CA Cancer J Clin. 2004; 54: 8-29.
2. Ursin G, Bernstein L, Pike MC. Breast cancer. Cancer Surv. 1994; 19-20: 21-264.
3. SampalisFS, DenisR, PicardD, FleiszerD,Martin G, NassifE, et al. International prospective evaluation ofscintimammography with technetium-99m sestamibi:
S.D.Ü. Tıp pak.
Derg
. 2007:14(3)/1-6
6
Çerçi, Meme kanserinde Tc-99m MIBI meme sintigrafisi
interim results. Am J Surg. 2001; 182(4): 399-403.
4. Danielsson R, Sanchez-Crespo A, Pegerfalk A, Grabowska H, Larsson SA, Bone B, et al. 99mTc-sestamibi uptake and histological malignancy grade in invasive breast carcinoma. Eur J Nucl Med. 2003; 30:
662-6.
5. Bone B, Apselin P, Bronge L, Veress B. Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. Acta Radiol. 1998; 39: 279-84.
6. Jackson VP. The role ofUS in breast imaging. Radiology. 1990; 177: 305-11.
7. Kopans DB. Sonography should not be used for breast cancer screening until its efficacy has been proven scientifically. AJR2004; 182: 489-91.
8. Whole-breast US imaging: four-year follow-up. Radiology. 1985; 157(2): 505-7.
9. The role of sestamibi scintigraphy in the radioisotopic assessment ofmyocardial viability. J NuclMed. 1992; 33(11):1925-30.
10. Hassan IM, Sahweil A, Constantinides C, Mahmoud A, Nair M, Omar YT, Abdeldayem HM. Uptake and kinetics ofTc99-m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med. 1989; 14:333-40 .
11. Palmedo H, Biersack HJ, Lastoria S, Maublant J, Prats E, Stegner HE, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results ofaprospective European multicentre trial.
Eur J Nucl Med. 1998; 25(4):375-85.
12. Turkish Society ofNuclear Medicine Nuclear Oncology Task Group. Procedure guideline for breast scintigraphy. TurkJNuclMed2001;4(S): 119-122.
13. Wolfe JN. Analysis of462 breast carsinoma. AJR 1974; 121: 846-9.
14. FletcherSW, BlackW, HarisR.Reportofthe international workshop on screening for breast cancer. JNatlCancerInst 1993; 85: 1644-56.
15. TabarL, DuffySW, KrusemoUB.Detectionmethod, tumor size and node metastases in breast cancer diagnosed during a trial ofbreast cancer screening. Eur J Cancer Clin Oncol 1987; 23: 959-62.
16. Andersson I. Mammographic screening and mortality from breast cancer: Malmö mammographic screening trial. BritJMed.1998;943-8.
17. Randomized study ofmammography screening-preliminary report on mortality in the Stockholm trial. BreastCancerResTreat. 1991 ;18(1):49-56.
18. Canada national breast screening study. Can Med Assoc J. 1992; 147:1459-76.
19. Reasons underlying negative mammography in patients with palpable breast cancer. Clin Radiol. 1994; 49(2):123-5.
20. Analysis ofcancers missed at screening mammography. Radiology. 1992;184 (3):613-7.
21. Kopans DB. The positive predictive value of
mammography. Am J Roentgenol. 1992; 158 (3): 521-6.
22. Comparison ofquantitative and visual analysis ofTc-99m MIBI scintimammography for detection ofprirnary breast cancer. Eur J Radiol. 2005;53(2):192-8.
23. Bird RE, Wallace TW, Yankaskas BC. Analysis of cancers missed at screening mammography. Radiology 1992; 184:613-7.
24. Holland R, Jan HC, Hendricks L, Mravunac M. Mammographically occult breast cancers:a pathological and radiologic study. Cancer 1983; 52: 1810-19.
25. Schillaci O, Buscombe JR. Breast scintigraphy today: indications and limitations. Eur J Nucl Med Mol Imaging. 2004;31 Suppl 1:S35-S45. Epub2004Apr23.
26. Palpable solid breast masses: retrospective single-andmultimodalityevaluationof 201 lesions. Radiology. 1988; 166(2): 435-9.
27. Breast cancer detection with sonography and mammography: comparison using state-of-the-art equipment. Am J Roentgenol. 1983;140(5):843-5.
28. Prone scintimammography in patients with suspicion of carcinoma of the breast. JAmColl Surg. 1994;178(5):491-7.
29. Breast cancer diagnosis by scintimammography: a meta-analysis and review ofthe literature. Breast Cancer Res Treat. 2003;80(1):115-26.
30. Sampalis FS, Denis R, Picard D, Fleiszer D, Martin G, NassifE, et al. International prospective evaluation of scintimammography with (99m)technetium sestamibi. Am J Surg 2003; 185: 544-9.
31. Uptake ofTc-99m MIBI related to tumour size and type. Anticancer Res. 1997; 17(B): 1693-4.
32. A three center study on the diagnostic accuracy of 99mTc-MIBI scintimammography. Anticancer Res. 1997;17(3B):1631-4.
33. Diagnostic accuracy of99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med. 2000;41(12):1973-9.
34. Gupta P, Waxman A, Nguyen K. Correlation ofTc-99m sestamibi uptake with histopathologic characteristics in patients with breast disease. J Nucl Med 1996; 37: 250.

Thank you for copying data from http://www.arastirmax.com